
    
      The B7601011 study has a randomized, double-blind, placebo-controlled parallel group design.
      Approximately 88 subjects will be randomized to 2 treatment groups. Each subject will
      participate in the study for approximately 23 weeks including a 30 day screening period, 15
      week double blind treatment period, and an approximately 28 day follow-up period.
    
  